title: Sch-27899 (Schering-Plough Corp).
abstract: Sch27899 (Ziracin) is an oligosaccharide antibiotic under development by Schering-Plough as a potential treatment for Gram-positive bacterial infection, including vancomycin- and methicillin-resistant bacteria. It is being evaluated in phase III clinical trials. Sch-27899 is a member of the naturally occurring class of everninomicins and was isolated from Micromonospora. Sch-27899 and the Micromonospora strain producing it were first disclosed in US04597968. The cyclodextrin complex, which overcomes the toxicity problems of Sch27899, is claimed in EP00538011.
authors.affiliation: Department of Haematology, University Hospital Gasthuisberg, KU Leuven, Herestraat 49, Leuven 3000, Belgium. johan.maertens@kuleuven.ac.be
authors.forename: J A
authors.initials: JA
authors.lastname: Maertens